2533.HK
WeRide, Pony AI makes infrastructure

Intelligent driving technology company Black Sesame International Holding Ltd. (2533.HK) said on Wednesday it will raise about HK$1.24 billion ($159 million) through a new share placement, becoming the latest Chinese tech company to capitalize on a recent wave of positive sentiment towards the group.

Black Sesame said it will sell 53.65 million shares, or 8.55% of its expanded share capital, at a placement price of HK$23.20, according to its announcement. The placement price represents an 11.8% discount to the stock’s last closing price before the announcement, but is roughly equal to its average trading price over the last five trading days. Black Sesame’s shares rose 3.2% on Wednesday to close at HK$27.15.

The company is the latest to take advantage of positive investor sentiment towards Chinese tech stocks to raise new cash. Other companies to similarly raise new funds include telecoms software maker Comba (2342.HK), intelligent driving technology firm iMotion (1274.HK) and AI drug-making services provider XtalPi (2228.HK).

By Doug Young

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…